Abstract
Introduction Cryptococcal meningitis remains a prominent cause of death in persons with advanced HIV disease. CSF leukocyte infiltration predicts survival at 18 weeks; however, how CSF immune response relates to CSF leukocyte infiltration is unknown.
Methods We enrolled 401 adults with HIV-associated cryptococcal meningitis in Uganda who received amphotericin and fluconazole induction therapy. We assessed the association of CSF leukocytes, chemokine, and cytokine responses with 18-week survival.
Results Participants with CSF leukocytes ≥50/µL, had higher probability 68% (52/77) of 18-week survival compared with 52% (151/292) 18-week survival in those with ≤50 cells/µL (Hazard Ratio=1.63, 95% confidence intervals 1.14-2.23; p=0.008). Survival was also associated with higher expression of T helper (Th)-1, Th17 cytokines, and immune regulatory elements. CSF levels of Programmed Death-1 Ligand, CXCL10, and Interleukin (IL)-2 independently predicted survival. In multivariate analysis, CSF leukocytes were inversely associated with CSF fungal burden and positively associated with CSF protein, interferon-gamma (IFN-γ), IL-17A, tumor necrosis factor (TNF)-α, and peripheral blood CD4+ and CD8+ T cells expression.
Conclusion 18-week survival after diagnosis of cryptococcal meningitis was associated with higher CSF leukocytes at baseline with greater T helper 1 (IFN-γ, IL-2 and TNF-α cytokines), T helper 17 (IL-17A cytokine) and CXCR3+ T cell (CXCL10 chemokine) responses. These results highlight the interdependent contribution of soluble and cellular immune responses in predicting survival with HIV-associated cryptococcal meningitis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the National Institutes of Health and National Institute of Allergy and Infectious Diseases (R01AI078934, R21NS065713, R01AI108479, T32AI055433; DBM, DRB, and R01 AI108479; JR), National Institute of Neurologic Diseases and Stroke; (R01NS086312 and R25TW009345, and K24AI096925; JR). Fogarty International Center training grant; (D43TW009771; YCM and PhD training scholarship; SO; R01NS086312; JR and Northern Pacific Global Health Fellowship Program award (D43TW009345; LT). GlaxoSmithKline Trust in Science Africa (COL100044928; SO). DELTAS Africa Initiative grant (DEL15011 to THRiVE2; DBM), Wellcome Trust grant (107742/Z/15/Z; DBM), and Veterans Affairs Research Service; (I01CX001464; ENJ), the Wellcome Trust (Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, grant number (087540; DBM). United Kingdom Medical Research Council/Wellcome Trust/Department for International Development (MRC MR/M007413/1; JR) and the Grand Challenges Canada (S4029601; JR). Funding agencies had no role in study design, data collection, data analysis, preparation of the manuscript, or the decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants or their surrogates provided written informed consent. The Mulago Hospital Research Ethics committee and University of Minnesota institutional review board approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
